PITTSBURGH , May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has more than 25 years of global biotechnology experience,

PITTSBURGH , April 27, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster presentation at the

PITTSBURGH , April 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the Statistical Analysis Plan (SAP) in the ongoing Phase 3 study of B-VEC for the treatment of dystrophic

New preclinical data from GLP toxicology and biodistribution study demonstrates in vivo safety of KB407 for cystic fibrosis Company expands rare genetic lung disease pipeline with KB408 for the treatment of alpha-1 antitrypsin deficiency PITTSBURGH , April 19, 2021 (GLOBE NEWSWIRE) -- Krystal

PITTSBURGH , March 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that enrollment is complete in the pivotal GEM-3 study of B-VEC for dystrophic epidermolysis bullosa (DEB).

PITTSBURGH , March 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming virtual conferences. Details for the presentations are as follows: Guggenheim Healthcare Talks:

-  Initial data from Cohort 1 of the PEARL-1 study shows safety and tolerability of repeat KB301 injections -  Dr. Bhushan Hardas M.D ., MBA appointed President, Jeune, Inc. PITTSBURGH , March 24, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable

- Enrollment anticipated to complete in 1Q21 and topline pivotal data from the GEM-3 study of B-VEC in DEB expected in 4Q21. - Today announced Positive Opinion from the European Medicines Agency on Orphan Drug Designation for KB407 for the treatment of cystic fibrosis.

PITTSBURGH , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that Krish S. Krishnan , Chairman and Chief Executive Officer will be participating in a fireside chat at the 41 st Annual

PITTSBURGH , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. (NASDAQ: KRYS) (the “Company), the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 1,923,077 shares of its common stock, at a public